المؤلفون: Watson S; Biomedical Ethics Research Program, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States., Benning TJ; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, United States., Marcon AR; Health Law Institute, University of Alberta, Edmonton, AB, Canada., Zhu X; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States., Caulfield T; Health Law Institute, University of Alberta, Edmonton, AB, Canada., Sharp RR; Biomedical Ethics Research Program, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.; Center for Individualized Medicine, Mayo Clinic, Rochester, MN, United States., Master Z; Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, United States.; Maya Angelou Center for Health Equity, Wake Forest University School of Medicine, Winston-Salem, NC, United States.; Center for Bioethics, Health and Society, Wake Forest University School of Medicine, Winston-Salem, NC, United States.; Wake Forest Institute of Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States.

المصدر: JMIR infodemiology [JMIR Infodemiology] 2024 Aug 29; Vol. 4, pp. e51328. Date of Electronic Publication: 2024 Aug 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: JMIR Publications Country of Publication: Canada NLM ID: 9918249014806676 Publication Model: Electronic Cited Medium: Internet ISSN: 2564-1891 (Electronic) Linking ISSN: 25641891 NLM ISO Abbreviation: JMIR Infodemiology Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19 Drug Treatment* , Alanine*/analogs & derivatives , Alanine*/therapeutic use , Adenosine Monophosphate*/analogs & derivatives , Adenosine Monophosphate*/therapeutic use , Hydroxychloroquine*/therapeutic use , COVID-19 Serotherapy*, Humans ; Uncertainty ; United States/epidemiology ; Immunization, Passive ; COVID-19/epidemiology ; COVID-19/prevention & control ; Mass Media ; Antiviral Agents/therapeutic use ; Evidence-Based Medicine ; SARS-CoV-2

المؤلفون: Piller C

المصدر: Science (New York, N.Y.) [Science] 2024 Sep 27; Vol. 385 (6716), pp. 1410. Date of Electronic Publication: 2024 Sep 26.

نوع المنشور: News

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19 Drug Treatment*, Humans

المؤلفون: Ben Abdallah H; Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark., Marino G; Department of Biomedicine, Aarhus University, Aarhus C, Denmark., Idorn M; Department of Biomedicine, Aarhus University, Aarhus C, Denmark., S Reinert L; Department of Biomedicine, Aarhus University, Aarhus C, Denmark., Bregnhøj A; Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark., Paludan SR; Department of Biomedicine, Aarhus University, Aarhus C, Denmark., Johansen C; Department of Dermatology, Aarhus University Hospital, Aarhus N, Denmark.

المصدر: PloS one [PLoS One] 2024 Sep 26; Vol. 19 (9), pp. e0310915. Date of Electronic Publication: 2024 Sep 26 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: HSP90 Heat-Shock Proteins*/antagonists & inhibitors , HSP90 Heat-Shock Proteins*/metabolism , SARS-CoV-2*/drug effects , SARS-CoV-2*/physiology , COVID-19*/virology , COVID-19 Drug Treatment* , Spike Glycoprotein, Coronavirus*/metabolism , Mice, Transgenic*, Animals ; Mice ; Humans ; Chlorocebus aethiops ; Vero Cells ; Inflammation/drug therapy ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Disease Models, Animal ; Cytokines/metabolism

المؤلفون: Tran KC; Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada., Asfar P; Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France., Cheng M; McGill's Interdisciplinary Initiative in Infection and Immunity, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada., Demiselle J; Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Singer J; Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada., Lee T; Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada., Sweet D; Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada., Boyd J; Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada., Walley K; Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada., Haljan G; Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada., Sharif O; Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada., Geri G; Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Ambroise Paré, Boulogne, France., Auchabie J; Service de Réanimation Polyvalente, Centre Hospitalier de Cholet., Quenot JP; Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire Dijon, Dijon, France., Lee TC; McGill's Interdisciplinary Initiative in Infection and Immunity, McGill University Health Centre, Montreal, Quebec, Canada., Tsang J; Niagara Health, McMaster University, St Catherines, Ontario, Canada., Meziani F; Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil Strasbourg, Strasbourg, France., Lamontagne F; Centre Hospitalier Universitaire de Sherbrooke, University of Sherbrooke, Quebec, Canada., Dubee V; Service de Maladies Infectieuses, Centre Hospitalier Universitaire d'Angers, Angers, France., Lasocki S; Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire Angers, Angers, France., Ovakim D; Royal Jubilee Hospital, Island Health, Victoria, British Columbia., Wood G; Royal Jubilee Hospital, Island Health, Victoria, British Columbia., Turgeon A; Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, Canada., Cohen Y; Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Avicenne, Bobigny, France., Lebas E; Service de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique, Vannes, France., Goudelin M; Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Limoges, Limoges, France., Forrest D; Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada., Teale A; Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada., Mira JP; Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris, Cochin, France., Fowler R; Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Daneman N; Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Adhikari NKJ; Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Gousseff M; Service de Médecine Interne-Maladies Infectieuses-Hématologie, Centre Hospitalier Bretagne-Atlantique, Vannes, France., Leroy P; Service de médecine polyvalente et maladies infectieuses, Centre Hospitalier Melun, Melun, France., Plantefeve G; Service de Réanimation Polyvalente, Centre Hospitalier Argenteuil, France., Rispal P; Department of Medicine, Service de médecine interne, Centre Hospitalier Agen, Agen, France., Courtois R; Service de Médecine post-urgences-Maladies infectieuses, Centre Hospitalier de Cholet, Cholet, France., Winston B; Departments of Critical Care Medicine, Medicine, and Biochemistry and Molecular Biology, Foothills Medical Centre, University of Calgary, Alberta, Canada., Reynolds S; Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.; Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada., Birks P; Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.; Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada., Bienvenu B; Service de médecine interne, Hôpital St Joseph, Marseille, France., Tadie JM; Service de Médecine Intensive-Réanimation et de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France., Talarmin JP; Service de médecine interne, maladies du sang et infectiologie, Centre Hospitalier de Quimper, Quimper, France., Ansart S; Service de Maladies Infectieuses, Centre Hospitalier Régional Universitaire Brest, Brest, France., Russell JA; Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.

مؤلفون مشاركون: ARBs CORONA II Team

المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Sep 26; Vol. 79 (3), pp. 615-625.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Losartan*/therapeutic use , Losartan*/adverse effects , Losartan*/administration & dosage , Hospitalization* , COVID-19*/mortality , COVID-19 Drug Treatment*, Humans ; Male ; Female ; Aged ; Middle Aged ; France/epidemiology ; Hospital Mortality ; SARS-CoV-2/drug effects ; Canada/epidemiology ; Aged, 80 and over ; Treatment Outcome ; Hypotension/chemically induced ; Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Angiotensin II Type 1 Receptor Blockers/adverse effects ; Angiotensin II Type 1 Receptor Blockers/administration & dosage ; Adult

المؤلفون: Lafont E; Department of Internal Medicine, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France., Blez D; Bacteriology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France., Bildan MA; Pharmacology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France., Veyer D; Virology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Unité mixte de recherche 1137, Infections Antimicrobials Modelling Evolution, Université Paris Cité, Paris, France.; Université Paris Cité, Paris, France., Péré H; Virology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.; Unité mixte de recherche 1137, Infections Antimicrobials Modelling Evolution, Université Paris Cité, Paris, France.; Université Paris Cité, Paris, France., Puech J; Virology Laboratory, Microbiology Department, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France., Kably B; Pharmacology Unit and Departement Medicaux Universitaire BIOPHYGEN, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.; Inserm Paris Cardiovascular Research Center UMRS970, Paris, France., Cheminet G; Department of Internal Medicine, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France., Pouchot J; Department of Internal Medicine, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, Paris, France., Thervet E; Université Paris Cité, Paris, France.; Nephrology Department, Hôpital Européen Georges Pompidou, AP-HP, Paris, France., Peytavin G; Université Paris Cité, Paris, France.; Pharmacology Department, Hôpital Bichat-Claude Bernard, AP-HP, Paris, France., Lazareth H; Université Paris Cité, Paris, France.; Nephrology Department, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.

المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Sep 26; Vol. 79 (3), pp. 798-800.

نوع المنشور: Letter; Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Ritonavir*/therapeutic use , Ritonavir*/administration & dosage , COVID-19 Drug Treatment* , Renal Insufficiency, Chronic*/complications , Drug Therapy, Combination*, Humans ; Male ; Aged ; Female ; SARS-CoV-2 ; Middle Aged ; Antiviral Agents/therapeutic use ; Antiviral Agents/administration & dosage ; COVID-19/complications

المؤلفون: Yan L; Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), Veterans Affairs Connecticut Health Care System, West Haven, Connecticut, USA.; Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA., Bui D; Veterans Affairs Portland Health Care System, Portland, Oregon, USA., Li Y; Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), Veterans Affairs Connecticut Health Care System, West Haven, Connecticut, USA.; Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, Connecticut, USA., Rajeevan N; Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), Veterans Affairs Connecticut Health Care System, West Haven, Connecticut, USA.; Biomedical Informatics & Data Science, Yale School of Medicine, New Haven, Connecticut, USA., Rowneki M; Center of Innovation to Improve Veteran Involvement in Care (CIVIC), Veterans Affairs Portland Healthcare System, Portland, Oregon, USA., Berry K; Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA., Argraves S; Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), Veterans Affairs Connecticut Health Care System, West Haven, Connecticut, USA., Huang Y; Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), Veterans Affairs Connecticut Health Care System, West Haven, Connecticut, USA.; Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA., Hynes DM; Center of Innovation to Improve Veteran Involvement in Care (CIVIC), Veterans Affairs Portland Healthcare System, Portland, Oregon, USA.; Health Management and Policy, School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences; Health Data and Informatics Program, Center for Quantitative Life Sciences, Oregon State University, Corvallis, Oregon, USA., Cunningham F; Veterans Affairs Center for Medication Safety-Pharmacy Benefit Management (PBM) Services, Hines, Illinois, USA., Huang GD; Office of Research and Development, Veterans Health Administration, Washington D.C., USA., Aslan M; Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center (CSP CERC), Veterans Affairs Connecticut Health Care System, West Haven, Connecticut, USA.; Office of Research and Development, Veterans Health Administration, Washington D.C., USA., Ioannou GN; Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.; Divisions of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington, USA., Bajema KL; Veterans Affairs Portland Health Care System, Portland, Oregon, USA.; Division of Infectious Diseases, Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.

المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Sep 26; Vol. 79 (3), pp. 643-651.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Ritonavir*/therapeutic use , Veterans* , COVID-19 Drug Treatment* , Hospitalization*/statistics & numerical data, Humans ; Male ; Aged ; Female ; Middle Aged ; SARS-CoV-2 ; Antiviral Agents/therapeutic use ; COVID-19/mortality ; COVID-19/epidemiology ; United States/epidemiology ; Indazoles/therapeutic use

المصدر: Drug and therapeutics bulletin [Drug Ther Bull] 2024 Sep 25; Vol. 62 (10), pp. 148. Date of Electronic Publication: 2024 Sep 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 0112037 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-5248 (Electronic) Linking ISSN: 00126543 NLM ISO Abbreviation: Drug Ther Bull Subsets: MEDLINE

مواضيع طبية MeSH: Ascorbic Acid*/administration & dosage , Ascorbic Acid*/therapeutic use , COVID-19 Drug Treatment* , Administration, Intravenous*, Humans ; Randomized Controlled Trials as Topic ; COVID-19 ; SARS-CoV-2 ; Vitamins/administration & dosage ; Vitamins/therapeutic use

المؤلفون: Bennett CL; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.; Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America., Magagnoli J; Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States of America., Gundabolu K; Division of Hematology/Oncology, Department of Internal Medicine, Omaha School of Medicine University of Nebraska, Omaha, Nebraska, United States of America., Georgantopoulos P; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Lebby A; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Watson G; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Knopf K; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.; Hematology/Oncology, Highland Hospital, Alameda Health System, Oakland, California, United States of America., Martin L; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Carson KR; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America.; Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine Northwestern University, Chicago, Illinois, United States of America., Hrushesky WJ; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Nabhan C; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Zyszkowski E; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Smith EB; Department of Southern Network on Adverse Reactions (SONAR), University of South Carolina, Columbia, South Carolina, United States of America., Gale RP; Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom., Rosen ST; City of Hope Comprehensive Cancer Center and the Beckman Research Institute, Duarte, California, United States of America.

المصدر: PloS one [PLoS One] 2024 Sep 25; Vol. 19 (9), pp. e0308205. Date of Electronic Publication: 2024 Sep 25 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Ritonavir*/therapeutic use , Ritonavir*/adverse effects , COVID-19 Drug Treatment* , COVID-19*/epidemiology , Social Media*, Humans ; SARS-CoV-2 ; Databases, Factual ; United States/epidemiology ; Antiviral Agents/therapeutic use ; Antiviral Agents/adverse effects ; Indazoles ; United States Food and Drug Administration

المؤلفون: Singh K; National Institute of Allergy and Infectious Diseases, Bethesda., Rubenstein K; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research., Callier V; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research., Shaw-Saliba K; National Institute of Allergy and Infectious Diseases, Bethesda., Rupert A; National Laboratory for Cancer Research, Frederick, Maryland., Dewar R; National Laboratory for Cancer Research, Frederick, Maryland., Laverdure S; National Laboratory for Cancer Research, Frederick, Maryland., Highbarger H; National Laboratory for Cancer Research, Frederick, Maryland., Lallemand P; National Laboratory for Cancer Research, Frederick, Maryland., Huang ML; Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington., Jerome KR; Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington.; Fred Hutchinson Cancer Center, Seattle, Washington., Sampoleo R; Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington., Mills MG; Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington., Greninger AL; Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington., Juneja K; Gilead Sciences, Inc, Foster City, California., Porter D; Gilead Sciences, Inc, Foster City, California., Benson CA; University of California San Diego., Dempsey W; National Institute of Allergy and Infectious Diseases, Bethesda., El Sahly HM; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas., Focht C; The Emmes Company, Rockville, Maryland., Jilg N; Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston., Paules CI; Division of Infectious Diseases, Milton S. Hershey Medical Center, Penn State Health, Hershey, Pennsylvania., Rapaka RR; Center for Vaccine Development and Global Health, School of Medicine, University of Maryland, Baltimore., Uyeki TM; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Clifford Lane H; National Institute of Allergy and Infectious Diseases, Bethesda., Beigel J; National Institute of Allergy and Infectious Diseases, Bethesda., Dodd LE; National Institute of Allergy and Infectious Diseases, Bethesda.

مؤلفون مشاركون: Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members

المصدر: The Journal of infectious diseases [J Infect Dis] 2024 Sep 23; Vol. 230 (3), pp. 624-634.

نوع المنشور: Journal Article; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

مواضيع طبية MeSH: Adenosine Monophosphate*/analogs & derivatives , Adenosine Monophosphate*/therapeutic use , Alanine*/analogs & derivatives , Alanine*/therapeutic use , SARS-CoV-2*/immunology , Antiviral Agents*/therapeutic use , COVID-19 Drug Treatment* , RNA, Viral*/blood , COVID-19*/blood , COVID-19*/virology , COVID-19*/immunology , Biomarkers*/blood , Viral Load*, Humans ; Male ; Female ; Middle Aged ; Treatment Outcome ; Adult ; Coronavirus Nucleocapsid Proteins/immunology ; Aged ; Antigens, Viral/blood

المؤلفون: Attiq A; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang, 11800, Malaysia., Afzal S; Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia., Wahab HA; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang, 11800, Malaysia., Ahmad W; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang, 11800, Malaysia., Kandeel M; Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.; Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrel Sheikh, 6860404, Egypt., Almofti YA; Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.; Department of Biochemistry, Molecular Biology and Bioinformatics, College of Veterinary Medicine, University of Bahri, Khartoum, 12217, Sudan., Alameen AO; Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.; Department of Physiology, Faculty of Veterinary Medicine, University of Khartoum, Shambat, 13314, Sudan., Wu YS; Sunway Microbiome Centre, School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, 47500, Malaysia.; Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, 47500, Malaysia.

المصدر: Drug design, development and therapy [Drug Des Devel Ther] 2024 Sep 20; Vol. 18, pp. 4215-4240. Date of Electronic Publication: 2024 Sep 20 (Print Publication: 2024).

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/complications , Cytokine Release Syndrome*/drug therapy , Cytokine Release Syndrome*/etiology , SARS-CoV-2* , COVID-19 Drug Treatment*, Humans ; Cytokines/metabolism ; Thyroid Diseases/drug therapy ; Thyroid Diseases/metabolism ; Angiotensin-Converting Enzyme 2/metabolism ; Thyroid Gland/metabolism ; Thyroid Gland/physiopathology